Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Jan 5;13(1):8. doi: 10.1038/s41408-022-00778-3

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2023

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 2 — A In the whole cohort [cumulative incidence of 18% (95% confidence interval 95%, 16–20%)]. B According to the use of corticosteroids at the time of first vaccine dose. [Under corticosteroids cumulative incidence of 24.5% (95% confidence interval, 19–30%) vs without 16.7%, 95% C.I. 14–18 (p < 0.001)]. C According to the patient’s gender. [Male 19.6% (95% confidence interval, 17–22.4%) vs. female 15.5%, 95% C.I. 13–18 (p = 0.04)]. D According to development of COVID-19 before the first vaccine dose. [Prior COVID-19 11% (95% confidence interval, 6–17%) vs without 18.4%, 95% C.I. 16–20.5, (p = 0.04)]. E According to chronic lymphocytic leukemia vs others. [CLL 29% (95% confidence interval, 22–36%) vs. others16.8%, 95% C.I. 15–18.9 (p < 0.001)]. F According to timing of last therapy. [No treated 21% (C.I. 95%, 16–26%) vs. active therapy 20.5%, 95% C.I. 18–24 vs 6 months to 1 year 16% (C.I. 95%, 10–22) vs. >1 year 14% (95% C.I., 12–17) (p = 0.04)].